RENODAPT-S is also known as Indian Generic Cellcept, is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. RENODAPT-S should be used concomitantly with cyclosporine and corticosteroids.
RENODAPT-S Intravenous is an alternative dosage form to RENODAPT-S capsules, tablets and oral suspension. RENODAPT-S Intravenous should be administered within 24 hours following transplantation. RENODAPT-S Intravenous can be administered for up to 14 days; patients should be switched to oral RENODAPT-S as soon as they can tolerate oral medication.
Allergic reactions to RENODAPT-S have been observed; therefore, RENODAPT-S is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. RENODAPT-S Intravenous is contraindicated in patients who are allergic to Polysorbate 80 (TWEEN).
The principal adverse reactions associated with the administration of RENODAPT-S include diarrhea, leukopenia, sepsis, vomiting, and there is evidence of a higher frequency of certain types of infections eg, opportunistic infection. The adverse event profile associated with the administration of RENODAPT-S Intravenous has been shown to be similar to that observed after administration of oral dosage forms of RENODAPT-S.